VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

NCRI 2021 | Developments in molecular radiotherapy

Jon Wadsley, MB, BChir, MA, MRCP, FRCR, Weston Park Cancer Centre, Sheffield, UK, discusses advancements in the field of molecular radiotherapy (MRT). Whilst MRT is predominantly used in rarer cancers such as thyroid cancer and neuroendocrine tumors, recent trials in the field of prostate cancer has demonstrated the potential utilization of MRT in more common cancers. Prof. Wadsley additionally highlights the need for individualized dosage of radiotherapy, as highlighted in the SELIMETRY trial (EudraCT No 2015-002269-47), which assessed selumetinib in resensitizing thyroid cancer to radioiodine therapy. This interview took place at the National Cancer Research Institute (NCRI) Festival 2021.


I have received research funding from AstraZeneca and Sanofi-Genzyme.

I have received honoraria from Eli Lilly, AstraZeneca, Sanofi-Genzyme, AAA, Roche, Novartis, Eisai, Ipsen

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter